A phase IIa trial investigating the cardiometabolic effects of gevokizumab in patients with type 2 diabetes mellitus.

Trial Profile

A phase IIa trial investigating the cardiometabolic effects of gevokizumab in patients with type 2 diabetes mellitus.

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2011

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors XOMA
  • Most Recent Events

    • 04 Aug 2011 Six-month top-line results reported in a XOMA Media Release.
    • 05 Oct 2009 New trial record.
    • 01 Oct 2009 This trial is in its final stages of design. XOMA anticipates initiating this trial in the first quarter of 2010, according to a company media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top